For production batches above 100 g of peptide, solvent extraction is preferred over solvent evaporation because it limits shear-induced aggregation of the disulfide-bridged cyclic peptide in poly(D,L-lactide-co-glycolide) microspheres. The aqueous peptide phase is adjusted to pH 4.0–4.5 with 0.1 M acetate buffer before primary emulsification. The organic phase is prepared by dissolving acid-terminated PLGA 50:50 or 75:25 in ethyl acetate or dichloromethane. Polymer molecular weight is controlled between 25,000 Da and 35,000 Da. Acid number is held at 3–12 mg KOH/g. A water-in-oil-in-water double emulsion is generated in a rotor-stator mixer at 5,000–10,000 rpm for 2–5 min. The continuous phase contains 0.5%–1.0% w/v polyvinyl alcohol or sodium cholate as surface stabilizer. The emulsion vessel is jacketed at 2–8 °C during high-shear mixing to slow disulfide exchange and tryptophan oxidation. Solvent removal is carried out at 30–40 °C under reduced pressure with ramp not exceeding 2 °C/min. The hardened microspheres are wet-sieved through a 150 µm mesh. Final particle size Dv50 is targeted at 30–80 µm and span below 1.2. Drug loading is limited to 5%–8% w/w. Loadings above 10% w/w produce a burst release above 15% of label claim within 24 h and increase the fraction of particles above 100 µm. Loadings below 3% w/w reduce cumulative release below 85% by day 28. Residual dichloromethane is controlled under the ICH Q3C Class 2 limit of 600 ppm; ethyl acetate is controlled under the ICH Q3C Class 3 limit of 5,000 ppm. Terminal sterilization is not applied because gamma irradiation at 25 kGy increases peptide-related impurities by more than 1.0% area by HPLC. The depot injection is administered through a 19–21 G needle. Syringeability is tested at 50 mm/min displacement and is considered acceptable when the glide force does not exceed 20 N. Published data for this specific configuration is limited at production scale, and the design space is established by formulation screening with differential scanning calorimetry and scanning electron microscopy.

Terminal Sterilization Destabilizes Saturated Octreotide Acetate Solutions Past pH 6.2

The molecular disulfide bridge between Cys² and Cys⁷ renders octreotide acetate vulnerable to oxidative rearrangement during terminal sterilization and to pH shifts above 6.2. Steam sterilization at 121 °C for 15 min has been observed to increase aggregate index by more than 2.0% in aqueous solution. For this reason, immediate-release injectable solutions are processed by aseptic filtration through a 0.45 µm prefilter and a 0.22 µm PVDF membrane. The formulation is prepared in sterile water for injection with 0.1 M acetate buffer at pH 4.0–4.5. Osmolality is adjusted to 270–330 mOsm/kg with mannitol or sodium chloride. Nitrogen or argon overlay is applied during filling to maintain headspace oxygen below 2% v/v. Type I borosilicate glass vials with fluoropolymer-coated stoppers are used because standard bromobutyl stoppers can release volatile sulfur compounds that accelerate peptide degradation. Finished solution is stored at 2–8 °C and protected from light. Release testing includes clarity and colour evaluation according to USP 1, particulate matter according to USP 788, sterility according to USP 71, and bacterial endotoxin according to USP 85. Subvisible particle limits are applied as ≤6,000 particles per container for particles ≥10 µm and ≤600 particles per container for particles ≥25 µm. The finished injection can be diluted in sodium chloride 0.9% w/v for intravenous infusion. Dilution stability is limited to 6 h at 25 °C because aggregate formation begins after prolonged exposure to neutral pH.

Before primary drying begins, lyophilized octreotide acetate formulations at 10 mg, 20 mg, and 30 mg dose strengths require collapse temperature mapping because the amorphous cake is kinetically unstable at product temperatures above −32 °C in mannitol-glycine systems. The formulation contains octreotide acetate at a peptide assay of 95.0%–105.0% on dried basis, mannitol as crystalline bulking agent at 30–50 mg/mL, glycine at 5–10 mg/mL, and a phosphate or acetate buffer at 1–10 mM. The solution is filtered through a 0.22 µm filter and filled into 5 mL or 10 mL Type I glass vials with a fill volume of 1.0–3.0 mL. The freezing step is conducted at −45 °C with an annealing hold at −15 °C for 2–4 h to crystallize mannitol. Primary drying is carried out at a shelf temperature of −20 °C to −10 °C and a chamber pressure of 50–150 mTorr; the product temperature is held below collapse temperature. Secondary drying is conducted at 30–35 °C for 6–12 h. Residual moisture is tested by Karl Fischer titration according to USP 921 and is constrained to ≤3.0% w/w. The cake must reconstitute with water for injection to a clear solution in ≤2 min without visible particles. The finished lyophilized injection is subjected to real-time and accelerated stability storage at 2–8 °C and 25 °C/60% RH. The moisture ingress rate through the stopper is considered acceptable if content remains above 95.0% of label claim after 12 months. Process failures at this stage are associated with mannitol crystallization above 20% w/w, which creates a fragile cake that collapses during shipping.

When Oral Peptide Permeation Windows Narrow Below 40 nm

When the biologically active peptide is formulated in an enteric-coated granule or capsule, the paracellular permeation window in the duodenum and jejunum is generally narrower than 40 nm. Octreotide acetate has an average molecular mass above 1,000 Da and a negative LogP, so the unmodified peptide does not achieve clinically useful absorption from the gastrointestinal tract. Caco-2 permeability studies typically return an apparent permeability coefficient below 1 × 10⁻⁶ cm/s for the unmodified peptide. Oral formulations therefore combine a permeation enhancer with a pH-triggered carrier system. Sodium caprate at 1%–3% w/w of granule mass and medium-chain fatty acid derivatives at 2%–5% w/w are used to open tight junctions. Chitosan-derived matrices at 0.5%–1.5% w/w are added for mucoadhesion. The peptide is layered onto microcrystalline cellulose spheres by top-spray fluidized-bed granulation. Inlet air temperature is maintained at 35–45 °C and product temperature at 28–32 °C. Spray rate is set at 0.8–1.2 g/min per kg of core material, and atomizing pressure is 0.8–1.2 bar. The enteric coating is applied to a weight gain of 10%–15% w/w using an aqueous dispersion of methacrylic acid-ethyl acrylate copolymer 1:1, usually Eudragit L 30 D-55. Triethyl citrate is added as plasticizer at 15%–20% w/w of polymer dry mass, and glyceryl monostearate is added at 3%–5% w/w as anti-tack. The coated granules are filled into hard hydroxypropyl methylcellulose capsules at a dose of 10 mg, 20 mg, or 30 mg. Release testing is performed with USP Apparatus II at 50 rpm. Acid-stage testing in 0.1 N HCl for 2 h requires release ≤10% of label claim. Buffer-stage testing at pH 6.8 requires release ≥80% within 60 min. Process failures arise when the coating film thickness is below 35 µm, because gastric acid can diffuse through pinholes and degrade the peptide. Thickness above 80 µm delays the pH-triggered dissolution beyond 90 min and reduces the absorption window. Published data for specific oral octreotide configurations is limited, and each formulation is qualified by fasted-state intestinal perfusion or in vivo pharmacokinetic screening in an appropriate model.

Does Residual TFA Content Govern cGMP Suitability for Peptide-Conjugate Precursor Routes?

Chelator conjugation to the free ε-amino group of Lys⁵ in octreotide is performed under controlled pH 6.5–7.5 using an active ester intermediate, typically DOTA-NHS or DOTA-tris(tBu)ester. Octreotide acetate is dissolved in anhydrous dimethylformamide or dimethyl sulfoxide at a peptide concentration of 20–50 mg/mL. The chelator active ester is added at a molar ratio of 1.2–1.5 mol/mol of peptide. N,N-diisopropylethylamine is added to maintain the pH during conjugation. The reaction is quenched after 4–6 h with glycine to consume unreacted chelator. The crude conjugate is purified by preparative reversed-phase high-performance liquid chromatography using a C18 column and a mobile phase of water/acetonitrile containing 0.1% trifluoroacetic acid. Fractions that contain the target mono-DOTA conjugate are pooled and subjected to ion exchange or reversed-phase salt exchange into acetate form. Residual TFA content is measured by ion chromatography and is controlled at ≤0.1% w/w for kit-form radiolabeling. This limit is critical because residual TFA shifts the final labeling buffer pH and interferes with 68Ga or 177Lu incorporation. The purified conjugate is lyophilized in sealed vials. Release criteria include peptide content by HPLC, residual solvents according to ICH Q3C, TFA by ion chromatography, and mass confirmation by LC-MS. The product is not itself radioactive; it is a cGMP precursor for subsequent radiolabeling in a radiopharmacy. Terminal finished goods are peptide-chelator conjugates with a chemical purity ≥98.5% area and a free chelator content ≤0.5% area. When the API is sourced with residual TFA above 0.3% w/w, additional lyophilization cycles are required to pass the specification. The production process is confined to facilities with controlled air quality for peptides and does not require a hot cell until radiolabeling.

In-Situ Phase Inversion Kinetics and Initial Burst Suppression in PLGA-NMP Depot Systems

In-situ gelling depot systems based on PLGA dissolved in N-methyl-2-pyrrolidone are feasible for the 10 mg, 20 mg, and 30 mg octreotide depot strengths. The formulation contains acid-terminated PLGA 50:50 at 20%–40% w/w dissolved in N-methyl-2-pyrrolidone at 60%–80% w/w. Octreotide acetate is dissolved or dispersed at 5%–10% w/w of total formulation. The solution viscosity is controlled between 20 Pa·s and 100 Pa·s at 25 °C to match a 19–21 G needle. Phase inversion begins when the depot contacts aqueous subcutaneous fluid. N-methyl-2-pyrrolidone diffuses out of the forming implant and water enters; the polymer precipitates and traps the peptide. Initial burst release is governed by solvent outflow rate and drug solubility in the water-rich phase. The burst can be suppressed below 10% of label claim at 24 h by increasing PLGA concentration above 30% w/w and by matching peptide particle size to a Dv90 below 30 µm. The resulting implant releases over 30–90 days depending on PLGA molar ratio and polymer molecular weight. Residual N-methyl-2-pyrrolidone is not treated as a simple residual solvent because it is an excipient in this dosage form; its local concentration is assessed by toxicological review rather than ICH Q3C limit. Aseptic manufacturing is required because the formulation cannot be terminally sterilized. The liquid depot is filled under nitrogen into single-dose syringes. Release testing of the finished combination includes viscosity, syringeability, osmolality, and in vitro release through dialysis membranes. Process failures arise when water ingress into the formulation during filling exceeds 1.0% w/w, because phase inversion can begin inside the syringe and produce an unfillable gel. The finished product is administered by subcutaneous injection and forms a solid implant at the injection site. Published data for this specific configuration is limited, and release profiles are qualified by in vivo pharmacokinetic studies.

During aseptic filling of octreotide acetate into dual-chamber or prefilled syringe cartridges, silicone oil and tungsten pin residuals are introduced that can accelerate aggregation if the formulation contains no stabilizing non-ionic surfactant. Polysorbate 20 at 0.01%–0.1% w/v is used to reduce air-water and oil-water interfacial aggregation. The formulation is prepared in an acetate buffer at pH 4.0–4.5 and filled into cyclo-olefin polymer or Type I glass syringes with fluoropolymer-coated plunger stoppers. Silicone oil is applied to the barrel at 0.5–1.5 mg per syringe to balance break-loose force and particle formation. Tungsten residual from the glass nozzle pin is controlled below 5 µg per syringe because tungsten leaches and forms oxidized species that can react with peptide disulfide bonds. The filling line operates at 0–8 °C. Headspace oxygen is limited to 2% v/v by vacuum stoppering. Terminal sterilization is not used; the solution is passed through a 0.22 µm sterilizing filter before filling. Finished drug-device combination products are tested under ISO 11040-4 for glass barrels, ISO 13485 for device quality management, and ISO 10993-18 for extractable and leachable chemical characterization. Functional testing includes break-loose force ≤25 N and glide force ≤15 N. The filled syringe is terminally inspected by automated vision systems for subvisible particles according to USP 790. The device can deliver a single dose of 10 mg, 20 mg, or 30 mg octreotide when paired with a reusable autoinjector. The extractable profile of the elastomer is screened in phosphate buffer at 40 °C for 30 days, and any individual extractable above 0.5 µg/mL triggers a safety assessment. Published data for specific elastomer grades is limited, so each supplier lot is qualified by high-performance liquid chromatography with UV and charged aerosol detection.